Therapeutic area
Neurology
Neurodegenerative disorders, central and peripheral nervous system conditions, movement disorders, and neurovascular disease.
Core & active disease programs
Alzheimer's Disease
$409.0B+ attributable cost
$27.0B$+ drug spend
126 assets · 3 indications
Migraine
$175.4B attributable cost
53 assets · 1 indication
Multiple Sclerosis
$65.6B+ attributable cost
$35.2B$+ drug spend
46 assets · 3 indications
Diabetic Peripheral Neuropathic Pain
$56.9B+ attributable cost
17 assets · 2 indications
Epilepsy
$40.8B+ attributable cost
$18.4B$+ drug spend
72 assets · 5 indications
Parkinson's Disease
$25.4B attributable cost
$4.1B$ drug spend
125 assets · 1 indication
Provisional & emerging programs (28)Early clinical pipeline & single-asset indications
Amyotrophic Lateral Sclerosis
Myasthenia Gravis
Narcolepsy
Huntington's Disease
Dravet Syndrome
Spinal Muscular Atrophy
Chronic Pain
Fibromyalgia
Spinocerebellar Ataxia
Acute Ischemic Stroke
Acute Pain
Alexander Disease
Cerebral Cavernous Malformation
Chronic Inflammatory Demyelinating Polyneuropathy
Chronic Low Back Pain
Dementia with Lewy Bodies
Developmental and Epileptic Encephalopathies
Essential Tremor
Friedreich Ataxia
Frontotemporal Dementia
Guillain-Barré Syndrome
Idiopathic Hypersomnia
Lennox-Gastaut Syndrome
Neurogenic Orthostatic Hypotension
Neuropathic Pain
Non-24-Hour Sleep-Wake Disorder
Subarachnoid Hemorrhage
Tardive Dyskinesia